The clinical data, including treatment outcomes, of 143 MDR-TB patients in Hangzhou Red Cross Hospital and Wenzhou Central Hospital from 2014 to 2016 were collected. All patients received cycloserine-containing standard treatment according to the World Health Organization Treatment Guidelines for Drug-resistant Tuberculosis, 2016 Update. The data such as treatment outcome, sputum negative conversion rate, and adverse events associated with drug were summarized.

Among the 143 patients treated with cycloserine-containing regimen, the overall treatment success rate achieved 69.2% (99/143). 81.1% (116/143) of patients had sputum culture conversion in the intensive phase. A total of 13 cases (9.1%, 13/143) reported adverse events that were considered to be related with cycloserine, including 7 cases who complained of dizziness or headache, 3 cases of limb numbness, 2 cases of limb twitch and 1 case of depression. All adverse events were relieved by dose reduction or symptomatic treatment.

Cycloserine-containing standard therapy has high overall success rate and well tolerance for MDR-TB patients, which is worth to be applied in clinical.